Acceptability of dihydroartemisinin-piperaquine as malaria intermittent preventive treatment for pregnant women living with HIV in Southern Mozambique
The acceptability of DHA-PPQ among HIVPW appears to be influenced more by trust in healthcare providers rather than by the perceived benefits of the medication itself. Leveraging this trust to enhance awareness and understanding of DHA-PPQ's benefits could further improve its acceptability. Moreover, further implementation research focused on acceptability in a real-world environment is essential to deepen the understanding of DHA-PPQ acceptability beyond the clinical trial setting, and inform policy decisions accordingly.
Authors
- Célia Chauque
- Tacilta Nhampossa (ORCID: https://orcid.org/0000-0002-4616-8752)
- Khátia Munguambe (ORCID: https://orcid.org/0000-0003-3888-5126)
- Esperança Sevene (ORCID: https://orcid.org/0000-0001-9025-4052)
- Clara Menéndez (ORCID: https://orcid.org/0000-0002-2641-6907)
- Raquel González (ORCID: https://orcid.org/0000-0001-5487-801X)
- Yara Alonso (ORCID: https://orcid.org/0000-0003-0183-5061)
- Mariza Chivangue
- Maura Mazuze
- Neusa Fernanda Torres (ORCID: https://orcid.org/0000-0001-7568-9971)
- Anete Mendes-Muxlhanga
- Cristina Enguita-FernàndezAnete
Institutions
- Eduardo Mondlane University (MZ)
- Departament de Salut (ES)
- Manhiça Health Research Centre (MZ)
- Barcelona Institute for Global Health (ES)
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- BMC Public Health
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1186/s12889-025-22644-0
- Primary Topic
- Malaria Research and Control
- Type
- article
- Field-Weighted Citation Impact
- 0.00